Clipping of news on Brazilian Culture, Law and Citizenship
23/07/2013
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Benlysta is indicated for patients in the active phase of the autoimmune disease
Annual treatment can cost up to R$ 57,000
RIO-The National Agency for Sanitary Surveillance (ANVISA) has approved the first drug blindfolded class of biologics in the country to control the symptoms of systemic lupus erimatoso - chronic inflammatory disease that affects about 65,000 people in Brazil, 90% women. The biological product is so named because it contains proteins produced by living organisms in the laboratory. The product is much more expensive than the standard treatment, but showed better efficacy and fewer side effects.
According to the manufacturer, the pharmaceutical GSK, Benlysta, trade name of the drug, it costs, on average, U.S. $ 3,800. The manufacturer notes that only patients with acute symptoms and are already standard treatment are indicated for the use of Benlysta. At the stage of disease activity, symptoms vary from a chronic fatigue and reddish spots on the skin to brain inflammation. Untreated, lupus can lead to kidney failure and diabetes.
While the traditional method of combating the symptoms of autoimmune disease costs about U.S. $ 2000 per year and are made mostly with drugs based on corticosteroids and immunosuppressive treatment with Benlysta can cost up to U.S. $ 57 000 per year. The application is made by intravenous infusion for up to 15 doses per year.
Read more about this topic in
© 1996-2013. All rights reserved Infoglobo Comunicação e Participações SA This material may not be published, broadcast, rewritten or redistributed without permission.
Source: The Globe - Online
Our news are taken in full from our partner sites. For this reason, we can not change the contents of the same even in cases of typos.
This article was translated by an automatic translation system, and was therefore not reviewed by people.